Division of Cancer Medicine, Department of Thoracic and Head/Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Division of Cancer Medicine, Department of Sarcoma Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX.
Clin Lung Cancer. 2014 Jan;15(1):21-51. doi: 10.1016/j.cllc.2013.11.009. Epub 2013 Nov 21.
The current pace of development of targeted agents in lung cancer is unprecedented. This rapid pace of development is facilitated by the identification of novel targets, development of new ways of inhibiting older and more familiar targets and some very innovative therapeutic engineering that allows us to inhibit multiple targets simultaneously. In this tabulated summary of over 320 targeted therapies currently in practice and in clinical trials for patients with lung cancer are listed. Given that the information included is constantly changing, the readers are encouraged to ascertain the current status of the ongoing clinical trials by checking the clinicaltrials.gov website. To facilitate this, a hyperlink for each agent is inserted in the left hand column of this reference tool. Compounds in pre-clinical development that have not yet entered clinical trials are not listed. Target therapies that are in clinical development but not enrolling lung cancer patients are also not included. Save for these exceptions the list is intended to be comprehensive. In conclusion, there are a plethora of novel agents currently in development for lung cancer. The emergence of these agents offers hope to a group of patients for whom progress has been slow until now. However dramatic improvements in survival have already been made in specific subsets of patients and this pace of advancements is only expected to accelerate dramatically for the foreseeable future.
目前肺癌靶向药物的发展速度前所未有。这种快速发展的速度得益于新靶点的发现、开发抑制旧靶点和更熟悉靶点的新方法，以及一些非常创新的治疗工程，这些方法使我们能够同时抑制多个靶点。在这个表格中总结了目前针对肺癌患者的 320 多种靶向治疗药物的现状，包括正在临床实践中和临床试验中的药物。鉴于所包含的信息在不断变化，鼓励读者通过检查 clinicaltrials.gov 网站来确定正在进行的临床试验的最新状态。为了便于此操作，在本参考工具的左侧列中为每个药物插入了超链接。尚未进入临床试验的临床前开发中的化合物未列出。尚未招募肺癌患者的临床开发中的靶向治疗药物也不包括在内。除了这些例外情况，该列表旨在全面。总之，目前有大量针对肺癌的新型药物正在开发中。这些药物的出现为迄今为止进展缓慢的一组患者带来了希望。然而，在特定的患者亚群中已经取得了显著的生存改善，并且在可预见的未来，这种进展速度预计只会急剧加速。
